2024
An Artificial Intelligence-Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma.
Li Q, Zhang W, Liao T, Gao Y, Zhang Y, Jin A, Ma B, Qu N, Zhang H, Zheng X, Li D, Yun X, Zhao J, Yu H, Gao M, Wang Y, Qian B. An Artificial Intelligence-Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma. Clinical Cancer Research 2024, 31: 139-150. PMID: 39535738, DOI: 10.1158/1078-0432.ccr-24-2356.Peer-Reviewed Original ResearchPapillary thyroid carcinomaPapillary thyroid carcinoma patientsDisease-free survivalThyroid carcinomaInflammatory subtypeRadiomics signatureTreatment responseSubtype of papillary thyroid carcinomaTianjin Medical University Cancer Institute and HospitalAssociated with poor disease-free survivalFudan University Shanghai Cancer CenterPoor disease-free survivalCancer Institute and HospitalTreatment response of patientsComplications risk stratificationShanghai Cancer CenterAnti-inflammatory traditional Chinese medicinesResponse of patientsPreoperative ultrasound imagingValidation set 2Clinicopathological variablesTraining set 1Evaluate prognosisPoor prognosisRisk stratification7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor
Balasubramanian P, Ladenheim A, Gilani S, Gibson C, Kunz P. 7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor. Journal Of The Endocrine Society 2024, 8: bvae163.2027. PMCID: PMC11453623, DOI: 10.1210/jendso/bvae163.2027.Peer-Reviewed Original ResearchLung neuroendocrine tumorsPapillary thyroid carcinomaNeuroendocrine tumorsThyroid carcinomaPapillary thyroid cancerIntrathyroidal metastasisThyroid cancerThyroid metastasisPET-CTThyroid nodulesMetastatic lung NETsLow-risk thyroid cancerLeft thyroid noduleCentral neck dissectionFDG PET-CTMedullary thyroid carcinomaTreatment response evaluationIncidental thyroid nodulesInitiation of treatmentYear old femaleDiagnosed primary malignancyRate of FDGCalcitonin stainingFinal pathologyNeck dissectionTERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao W, Simsir A, Liu X, Brandler T, Cai G. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal Of Clinical Pathology 2024, 163: 251-257. PMID: 39250709, DOI: 10.1093/ajcp/aqae117.Peer-Reviewed Original ResearchTERT promoter mutationsHistopathologic follow-upFine-needle aspirationTERT mutationsMolecular alterationsFollow-upPromoter mutationsThyroid carcinomaFine-needle aspiration diagnosisFine-needle aspiration specimensThyroid fine-needle aspiration specimensBenign thyroid neoplasmsSurgical follow-upAssociated with malignancyMulti-institutional studyThyroSeq v3Thyroid neoplasmsAspiration specimensTumor behaviorMalignant neoplasmsCarcinomaMalignancyNeoplasmsThyroidMutationsEIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices
Abi-Raad R, Xu B, Gilani S, Ghossein R, Prasad M. EIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices. Virchows Archiv 2024, 485: 859-867. PMID: 39225726, PMCID: PMC11912518, DOI: 10.1007/s00428-024-03914-5.Peer-Reviewed Original ResearchFollicular nodular diseaseAnaplastic thyroid carcinomaPapillary thyroid carcinomaEIF1AX mutationsBenign thyroid nodulesThyroid carcinomaThyroid nodulesOncocytic adenomasMolecular alterationsGenetic abnormalitiesNon-invasive follicular thyroid neoplasmPapillary-like nuclear featuresAssociated with malignant tumorsWHO 5th EditionCancer referral centerFollicular thyroid neoplasmTertiary care hospitalOncocytic carcinomaThyroid neoplasmsReferral centerNodular diseasePathological diagnosisCancer Genome AtlasMalignant tumorsEIF1AXSeven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents
Williams M, Liu Z, Rossi E, Agarwal S, Ryška A, Al Ghuzlan A, Bychkov A, Baloch Z, Chernock R, Chiosea S, Cipriani N, Erkilic S, Fridman M, Hang J, Harahap A, Jung C, Kakudo K, Khalil M, Khanafshar E, Kumarasinghe P, Lloyd R, Nguyen T, Ocal I, Prasad M, Pusztaszeri M, Rana C, Sadow P, Sajed D, Seethala R, Tallini G, Vuong H, Yegen G, LiVolsi V, Nikiforov Y. Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 166-175. PMID: 38874075, DOI: 10.1210/clinem/dgae354.Peer-Reviewed Original ResearchPapillary-like nuclear featuresFollicular thyroid neoplasmPapillary thyroid carcinomaNuclear scoreThyroid neoplasmsWhole slide imagesEncapsulated follicular variant of papillary thyroid carcinomaFollicular variant of papillary thyroid carcinomaNoninvasive encapsulated follicular variant of papillary thyroid carcinomaVariant of papillary thyroid carcinomaNuclear featuresNoninvasive follicular thyroid neoplasmNon-invasive follicular thyroid neoplasmIncidence of NIFTPAdoption rateSlide imagesDiagnosing NIFTPNIFTP diagnosisThyroid carcinomaEndocrine pathologistsNIFTPDiagnosing lesionsNorth AmericaDiagnostic approachPractice patternsPhase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-freeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposureCirculating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women
Rinaldi S, Dossus L, Keski‐Rahkonen P, Kiss A, Navionis A, Biessy C, Travis R, Weiderpass E, Romieu I, Eriksen A, Tjonneland A, Kvaskoff M, Canonico M, Truong T, Katzke V, Kaaks R, Catalano A, Panico S, Masala G, Tumino R, Lukic M, Olsen K, Zamora‐Ros R, Santiuste C, Atxega A, Guevara M, Rodriguez‐Barranco M, Sandstrom M, Hennings J, Almquist M, Kouassivi E, Christakoudi S, Gunter M, Franceschi S. Circulating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women. International Journal Of Cancer 2024, 154: 2064-2074. PMID: 38357914, DOI: 10.1002/ijc.34872.Peer-Reviewed Original ResearchConceptsSex hormone binding globulinSex steroid hormonesThyroid cancerRisk of differentiated thyroid carcinomaOdds ratioSex steroidsSex hormone binding globulin concentrationsSteroid hormonesCancer-free controlsPre-menopausal womenRisk of differentiated TCEuropean Prospective InvestigationPost-menopausal womenEndogenous sex steroidsBorderline significant increaseConditional logistic regression modelsSex steroid productionNo significant associationCirculating sex steroidsCirculating sex steroid hormonesPostmenopausal womenConcentrations of testosteroneProgesterone/estradiol ratioThyroid carcinomaBorderline decrease
2023
Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective
Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R, Christison-Lagay E, Pashnakar F, Berry J, O'Neill A, Vasta L, Flynn A, Mitchell S, Seynnaeve B, Rosenblum J, Potter S, Kamihara J, Rodriguez-Galindo C, Hawkins D, Laetsch T. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. 2023, 2: 100024. PMID: 37829670, PMCID: PMC10566015, DOI: 10.1016/j.ejcped.2023.100024.Peer-Reviewed Original ResearchTumor CommitteeStromal tumorsDesmoplastic small round cell tumorSmall round cell tumorGastrointestinal stromal tumorsNonmelanoma skin cancerRound cell tumorGonadal stromal tumorPleuropulmonary blastomaRare tumorAdrenocortical carcinomaNeuroendocrine tumorsCell tumorsRare cancersChildhood cancerColorectal carcinomaPancreatic tumorsNasopharyngeal carcinomaThyroid carcinomaHigh-quality researchCarcinomaSkin cancerTumorsYoung adultsCancerChildren's Oncology Group's 2023 blueprint for research: Rare tumors
Schultz K, Chintagumpala M, Piao J, Chen K, Gartrell R, Christison‐Lagay E, Berry J, Shah R, Laetsch T, Committee T. Children's Oncology Group's 2023 blueprint for research: Rare tumors. Pediatric Blood & Cancer 2023, 70: e30574. PMID: 37458616, PMCID: PMC10529839, DOI: 10.1002/pbc.30574.Peer-Reviewed Original ResearchGrading system for medullary thyroid carcinoma; an institutional experience
Podany P, Meiklejohn K, Garritano J, Holt E, Barbieri A, Prasad M, Gilani S. Grading system for medullary thyroid carcinoma; an institutional experience. Annals Of Diagnostic Pathology 2023, 64: 152112. PMID: 36736129, DOI: 10.1016/j.anndiagpath.2023.152112.Peer-Reviewed Original ResearchConceptsMedullary thyroid carcinomaTwo-tier grading systemDistant metastasisNuclear pleomorphismGrading systemNodal diseaseOverall survivalVascular invasionMTC casesThyroid carcinomaMedullary thyroid carcinoma casesMultivariate Cox regressionThyroid carcinoma casesCohort of casesRisk stratificationCox regressionTumor gradePathology reportsCarcinoma casesInstitutional experienceThyroid malignancyTumor fibrosisHG groupProminent nucleoliRare type
2021
Impact of Transoral Endoscopic Vestibular Approach Thyroidectomy on Pathologic Assessment.
Smith SM, Ahmed M, Carling T, Udelsman R, Adeniran AJ, Gilani S, Prasad ML, Barbieri AL. Impact of Transoral Endoscopic Vestibular Approach Thyroidectomy on Pathologic Assessment. Archives Of Pathology & Laboratory Medicine 2021, 146: 879-885. PMID: 34669921, DOI: 10.5858/arpa.2021-0082-oa.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaMargin statusFinal diagnosisThyroid carcinomaCytologic diagnosisEndoscopic thyroid resectionUndetermined significance/Surgical resection specimensPreoperative cytologic diagnosisPathologic assessmentClinical followIndolent neoplasmClinicopathologic featuresThyroid resectionVestibular approachMean agePathologic examinationPreoperative imagingTumor sizeResection specimensPathologic parametersMalignant diagnosisFollicular lesionsFollicular neoplasmSurgical pathologyAnaplastic Thyroid Carcinoma: Cytomorphologic Features on Fine-Needle Aspiration and Associated Diagnostic Challenges
Podany P, Abi-Raad R, Barbieri A, Garritano J, Prasad ML, Cai G, Adeniran AJ, Gilani SM. Anaplastic Thyroid Carcinoma: Cytomorphologic Features on Fine-Needle Aspiration and Associated Diagnostic Challenges. American Journal Of Clinical Pathology 2021, 157: 608-619. PMID: 34661606, PMCID: PMC8973262, DOI: 10.1093/ajcp/aqab159.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnaplastic thyroid carcinomaFine-needle aspirationCytologic featuresATC casesTumor cellsThyroid carcinomaControl groupDiagnosis of ATCAcute inflammatory cellsKey cytologic featuresNuclear membrane irregularitySingle tumor cellsAggressive malignancyInflammatory cellsClinical historyDiagnostic challengePatient prognosisInclusion criteriaNeedle aspirationCytomorphologic featuresEarly diagnosisEpithelioid cytomorphologyNuclear pleomorphismAvailable slidesElectronic databasesHyalinizing trabecular tumor: Cytologic, histologic and molecular features and diagnostic considerations
Podany P, Gilani SM. Hyalinizing trabecular tumor: Cytologic, histologic and molecular features and diagnostic considerations. Annals Of Diagnostic Pathology 2021, 54: 151803. PMID: 34385072, DOI: 10.1016/j.anndiagpath.2021.151803.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTrabecular tumorThyroid carcinomaFine needle aspiration cytologyIntrathyroidal parathyroid tissueMedullary thyroid carcinomaNeedle aspiration cytologyPapillary thyroid carcinomaMolecular featuresMetastatic diseasePotential mimickersParathyroid tissueSolitary massDiagnostic considerationsAspiration cytologyProper diagnosisAppropriate managementMorphologic featuresTumorsCarcinomaNeoplasmsCytologicMimickersDiagnosisAnaplastic thyroid carcinoma: diagnostic challenges, histopathologic features and ancillary testing
Gilani S, Khan M, Barbieri A, Prasad M. Anaplastic thyroid carcinoma: diagnostic challenges, histopathologic features and ancillary testing. Diagnostic Histopathology 2021, 27: 263-271. DOI: 10.1016/j.mpdhp.2021.03.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnaplastic thyroid carcinomaDiagnostic challengeAggressive thyroid malignancyHigh mortality rateThyroid follicular cellsCompressive symptomsHistopathologic featuresCarcinoma componentThyroid malignancyAncillary testingThyroid carcinomaMortality rateDiagnostic limitationsFollicular cellsHistopathologic variabilityPaucicellular specimensMalignancyMolecular featuresPainCarcinomaSymptomsChange of Therapeutic Response Classification According to Recombinant Human Thyrotropin-Stimulated Thyroglobulin Measured at Different Time Points in Papillary Thyroid Carcinoma
Moon J, Jeon S, Park K, Yoo S, Kang S, Cho S, Kim J, Lee C, Song H, Min J, Bom H, Kwon S. Change of Therapeutic Response Classification According to Recombinant Human Thyrotropin-Stimulated Thyroglobulin Measured at Different Time Points in Papillary Thyroid Carcinoma. Nuclear Medicine And Molecular Imaging 2021, 55: 116-122. PMID: 34093891, PMCID: PMC8139997, DOI: 10.1007/s13139-021-00699-2.Peer-Reviewed Original ResearchPapillary thyroid carcinomaRadioactive iodineResponse classificationThyroid carcinomaSerum TGPapillary thyroid carcinoma patientsFollow-up of patientsInjection of rhTSHSerum Tg measurementsBiochemical incomplete responseRadioactive iodine therapyOptimal cutoff valueSerum TG levelsTime pointsSerum levelsTherapeutic responseTG levelsIndeterminate responseFollow-upMethodsA totalIncomplete responsePatientsSerumAssessed 6Excellent response
2020
Cytomorphologic features of thyroid disease in patients with DICER1 mutations: A report of cytology–histopathology correlation in 7 patients
Darbinyan A, Morotti R, Cai G, Prasad ML, Christison‐Lagay E, Dinauer C, Adeniran AJ. Cytomorphologic features of thyroid disease in patients with DICER1 mutations: A report of cytology–histopathology correlation in 7 patients. Cancer Cytopathology 2020, 128: 746-756. PMID: 32897650, DOI: 10.1002/cncy.22329.Peer-Reviewed Original ResearchConceptsDICER1 mutationsThyroid diseaseThyroid carcinomaScreening of patientsFine-needle aspiration samplesMonitoring of patientsDiagnostic cytologic featuresPapillary thyroid carcinomaGermline DICER1 mutationsThyroid fine-needle aspiration samplesFNA evaluationUndetermined significanceDifferent somatic variantsThyroid cancerScant colloidNeoplastic lesionsHistopathological analysisCytomorphologic featuresDICER1 syndromeModerate cellularityCytologic featuresFollicular carcinomaFollicular lesionsInconspicuous nucleoliFollicular neoplasmCombined role of lymph node ratio and serum thyroglobulin levels in predicting prognosis of papillary thyroid carcinoma.
Jeon S, Kwon S, Ryu Y, Kang S, Yoo S, Cho S, Kim J, Song H, Sohn S, Bom H, Min J. Combined role of lymph node ratio and serum thyroglobulin levels in predicting prognosis of papillary thyroid carcinoma. Nuclear Medicine Communications 2020, 41: 733-739. PMID: 32427697, DOI: 10.1097/mnm.0000000000001214.Peer-Reviewed Original ResearchConceptsLymph node ratioPapillary thyroid cancerMetastatic lymph nodesLymph nodesNode ratioRadioactive iodineTSH-stimulated serum thyroglobulinPrognosis of papillary thyroid carcinomaPostoperative RAI therapySerum thyroglobulin levelsPapillary thyroid carcinomaPrognosis of patientsSerum thyroglobulinSTg levelNeck dissectionRAI therapyThyroglobulin levelsRecurrent diseaseThyroid carcinomaPrognostic valueThyroid cancerPredicting prognosisRetrospective studyUnivariate analysisMultivariate analysisPediatric differentiated thyroid carcinoma: An update from the APSA Cancer Committee
Christison-Lagay ER, Baertschiger RM, Dinauer C, Francis G, Malek M, Lautz T, Aldrink J, Grant C, Rhee D, Ehrlich P, Dasgupta R, Abdessalam S, Committee O. Pediatric differentiated thyroid carcinoma: An update from the APSA Cancer Committee. Journal Of Pediatric Surgery 2020, 55: 2273-2283. PMID: 32553450, DOI: 10.1016/j.jpedsurg.2020.05.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsThyroid cancerPediatric DTCAPSA Cancer CommitteeSurgical therapeutic approachUnresectable progressive diseaseLymph node basinCornerstone of treatmentAutoimmune thyroid diseaseLong-term recurrenceFine-needle aspirationNode basinTotal thyroidectomyProgressive diseaseSurgical resectionRadiological featuresSurvival outcomesCancer CommitteeThyroid diseaseTreatment strategiesFamily historyTreatment decisionsNeedle aspirationTherapeutic approachesThyroid carcinomaIodine deficiencyOptimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma
Yoo S, Chowdhury S, Jeon S, Kang S, Cho S, Kim J, Lee C, Ryu Y, Song H, Bom H, Min J, Kwon S. Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma. Cancers 2020, 12: 262. PMID: 31978980, PMCID: PMC7072233, DOI: 10.3390/cancers12020262.Peer-Reviewed Original ResearchRadioactive iodine therapyRadioactive iodineSerum thyroglobulinThyroid carcinomaTherapeutic responseExcellent responsePost-therapeutic I-131 whole body scanI-131 whole body scanDifferentiated thyroid carcinomaWhole-body scanThyroid tissue damageTg cutoffThyroidectomy bedFocal uptakeSerum TGUptake groupTG groupAnterior midlinePatientsTissue damageTherapyBody scanRxWBSThyroidectomyCarcinoma
2019
Squamous cell carcinoma of the lung and pulmonary metastasis of papillary thyroid carcinoma: a case report
Aminorroaya A, Khoshniatnikoo M, Farrokhpour H, Vafaeimanesh J, Bagherzadeh M. Squamous cell carcinoma of the lung and pulmonary metastasis of papillary thyroid carcinoma: a case report. Journal Of Medical Case Reports 2019, 13: 259. PMID: 31422769, PMCID: PMC6699065, DOI: 10.1186/s13256-019-2177-6.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaSquamous cell carcinomaMetastasis of papillary thyroid carcinomaRadioactive iodine therapyThyroid carcinomaCell carcinomaIodine therapyPulmonary metastasesHistory of papillary thyroid carcinomaTumor-to-tumor metastasis phenomenonPositron emission tomography/computed tomography scanCervical lymph node dissectionCoexisting papillary thyroid carcinomaConcurrent squamous cell carcinomaRadioactive iodine uptake scanPrimary squamous cell carcinomaPapillary thyroid carcinoma metastasisPara-aortic lymphadenopathyThyroid carcinoma metastasisLymph node dissectionCoexistence of malignancyMonths of chemotherapyTumor to tumorPeritoneal carcinomatosisMetastatic involvement
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply